Biblio print

Tree Display

AceDB Schema

XML Display


Paper(s) concerning Memogain

3 reference(s) found.
Listing paper details in reverse chronological order.
We are grateful to Keith Bradnam for improvment of this script

    Title: First in human study with a prodrug of galantamine: Improved benefit-risk ratio?
    Baakman AC, t Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A, Groeneveld GJ
    Ref: Alzheimers Dement (N Y), 2:13, 2016 : PubMed


    Title: Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice
    Bhattacharya S, Maelicke A, Montag D
    Ref: J Alzheimers Dis, 46:123, 2015 : PubMed


    Title: Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy
    Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AK
    Ref: Journal of Molecular Neuroscience, 40:135, 2010 : PubMed


Send your questions or comments to :
Mail to: Nicolas Lenfant, Thierry Hotelier, Yves Bourne, Pascale Marchot and Arnaud Chatonnet.
Please cite: Lenfant 2013 Nucleic.Acids.Res. or Marchot Chatonnet 2012 Prot.Pept Lett.
For technical information about these pages see:
ESTHER Home Page and ACEDB Home Page
AcePerl Lincoln Stein Home Page

Acknowledgements and disclaimer